Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 19/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | ESRRG | P62508 | 8/20 | 0.49 |
| ▸ | ESRRB | O95718 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4668900 | 0.93 | ESR1 (0.55) | ESR1ESR2CYP19A1ESRRGESRRB | |
| SCHEMBL4667511 | 0.93 | ESR1 (0.59) | ESR1ESR2CYP19A1ESRRGESRRB | |
| SCHEMBL4894346 | 0.90 | ESRRG (0.49) | ESR1ESRRG | |
| SCHEMBL4667554 | 0.89 | CYP19A1 (0.64) | ESR1ESR2CYP19A1ESRRGESRRB | |
| SCHEMBL3817783 | 0.87 | ESR1 (0.62) | ESR1ESR2CYP19A1ESRRGESRRB | |
| SCHEMBL4665856 | 0.86 | CYP19A1 (0.60) | ESR1ESR2CYP19A1ESRRGESRRB | |
| SCHEMBL4666272 | 0.84 | ESR1 (0.57) | ESR1ESR2CYP19A1ESRRGESRRB | |
| SCHEMBL4637991 | 0.83 | ESR1 (0.71) | ESR1ESR2ESRRGESRRB | |
| SCHEMBL4796083 | 0.82 | ESR1 (0.53) | ESR1ESR2CYP19A1 | |
| SCHEMBL5052671 | 0.81 | ESR1 (0.51) | ESR1ESR2CYP19A1ESRRGESRRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951216-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | claimed |
| WO-2007062145-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | claimed |
| US-20080255078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | KATAMREDDY SUBBA REDDY | 2008-10-16 | — | — | US | disclosed |
| US-20080255078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | KATAMREDDY SUBBA REDDY | 2008-10-16 | — | — | US | disclosed |
| US-20080255078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | KATAMREDDY SUBBA REDDY | 2008-10-16 | — | — | US | disclosed |
| EP-1951216-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007062145-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | GPER1, ESR2, ESRRG | ESR1 4/4885ESR2 2/4885CYP19A1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.